(LMT) Lombard Medical Techs

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Pythagoras study data on Aorfix™ presented at ISET symposium in Miami

London, UK, 19 January 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, today announces that data from the US Pythagoras trial of its endovascular stent graft Aorfix™ was presented at the 24th annual International Symposium on Endovascular Therapy (ISET) on 15-19 January in Miami. The Pythagoras trial, data from which was also presented at the VEITH symposium in New York in November 2011, was designed to show the potential that Aorfix™ has to treat a larger patient population than competing devices, including both standard and difficult to treat cases of Abdominal Aortic Aneurysms (AAAs). 

Dr William Gray, Director of Endovascular Services at Columbia University Medical Center, New York, who presented results from patients with standard anatomy in the Pythagoras trial, commented:

"Aorfix™ has produced promising results in this patient group and in my experience, the results in tortuous anatomies are also very encouraging. It is significant that the majority of patients even in this group with normal anatomy had neck angles greater than 45°.  Aorfix™ should provide clinicians with a new treatment option which is both safe and versatile. Clinical practice is increasingly moving towards endovascular aneurysm repair and away from surgery, and devices that both perform well and are flexible such as Aorfix™ will play an important role as a highly effective option for patients with more complex anatomy and increase the number of patients for whom a non-operative AAA repair is possible."

Pythagoras is the largest prospective controlled study in the world involving patients with highly tortuous aortic and iliac anatomy, consisted of two groups of patients. The study group consisted of 150 caseswith aortic neck angles ≥ 60° and a 'roll-in' group of 62 patients with aortic neck angles < 60°.

Dr Gray presented data from the roll-in group and reported excellent results including:

·     No cases of graft failing to seal against the artery wall and no cases where the graft leaked at either 30 days or 1 year post-operatively

·     The absence of any reported graft migration or fracture at either 30 days or 1 year

·     In all cases the aneurysm sac decreased in diameter or remained stable after implantation of Aorfix™

The International Symposium on Endovascular Therapy (ISET) brings together practitioners in the fields of interventional radiology, vascular surgery, interventional cardiology and cardiothoracic surgery and others who specialize in treating cardiovascular disease. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means.

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.1 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death.  Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015.  The Company's lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease.  Aorfix™ is currently being commercialised in the EU, and has been submitted to the FDA for approval in the U.S. 

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com.

For further information: